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1111-138 Why ICD Pat ients  With Heart  Fai lure (Class II-IV) Are 
Hospitalized: Do the Reasons Differ for Patients Who 
Are Treated With Cardlec Reeynchronizatlon Therapy? 
John P. Boehmer. Teresa DeMarco, Brian E. Jaski, Mark D. Carlson, Vicki L. Rathbun, 
Chelsey M, Schmeichel, Guidant Corporation, St. Paul, Minnesota. 
Background: Cardiac resynchronization therapy (CRT) is currently being tested as an 
adjunct therapy to treat heart failure (HF). The VENTAK CHF/CONTAK CD study, a multi- 
center double-blind study, enrolled patients with HF who also met the general indications 
for an ICD, It is not known if this HF population that also requires an ICD is hospitalized 
for different reasons than the HF population as a whole or if CRT changes the rate or rea- 
sons for hospitalization, 
Methods: 501 patients (Age:66 _+ 10 years, QRS:158 ms + 26, NYHA Class III 58%, 
LVEF 21,5 ± 6,6%, Ischemic etiology 68,9%) were implanted with a CRT/ICD system and 
were randomized to CRT or no CRT. The reason for all hospitalizations were adjudicated 
by an independent events committee that was blinded to pacing mode, and were classi- 
fied as CHF related, other cardiac or non-cardiac, 
Results: There were 231 hospitalizations for ICD patients with symptomatic HF. The 
addition of CRT did not significantly change the rate of hospitalizations or the reasons for 
being hospitalized. 
CRT CRT No CRT No CRT Total Total 
Reason for Hospitalization Patients Events Patients Events Patients Events 
CHF 32 50 39 56 71 106 
Cardiac - other 20 40 25 31 45 71 
Noncardiac 26 30 19 24 45 54 
Total 66 120 70 111 136 231 
Conclusion: CRT does not effect the frequency or reason of hospitalization in patients 
with heart failure receiving an ICD. The most common reason for hospitalization is heart 
failure. 
1111-139 Long-Term Improvement in Functional Statue, Quality 
of Life and Exercise Capac i ty  With Cardiac 
Reeynchronization Therapy: The MIRACLE Trial 
Experience 
William T. Abraham, Westby Fisher, Andrew Smith, David DeLurgio, Angel Leon, Evan 
Loh, Dusan Kocovic, Alfredo Clavell, David Hayes, Anthony Tang, Ven Manda, Susan 
Petersen-Stajskal, University of Kentucky, Lexington, Kentucky, Crewford Long/Emory 
Univ, Univ of Pennsylvania, Mayo Clinic, Uoiv of Ottawa, Medtronic. 
Background: Moderate-to-severe Congestive Heart Failure (CHF) patients (pts) with a 
prolonged QRS duration(>130 ms) enrolled in the Multicenter lnSync Randomized Con- 
trolled Evaluation (MIRACLE) Trial improved their functional status, quality of life and 
exercise tolerance during a 6 month double-blind evaluation of cardiac resynchronization 
therapy (CRT). The purpose of this analysis is to examine the long-term impact of CRT 
on the endpoints of Six-minute Hall Walk Distance (HWK), Minnesota Living with Heart 
Failure Quality of Life Score (QOL), NYHA Functional Class (NYHA) and Exercise Dura- 
tion (EXT) on a Treadmill. 
Methods: Pts that received 12 months of CRT in the MIRACLE trial were included in this 
evaluation. Endpoints were assessed using pts as their own controls. All tests of signfi- 
cance are based on the Wilcoxon Signed Rank Test. 
Results: 67 pts received CRT for a period of 12 rods (mean age(years): 62.4 ± 11.7; 
LVEF (%): 22.4 ± 5.8; LVEDD (ram): 69.7 ± 10.5; 75% male; ORS duration (ms): 164 ± 
18. Improvements in HWK, QOL, NYHA and EXT from baseline to 6 months and base- 
line to 12 months are shown in the Table. 
Endpoint Baseline to 6 months p-value Baseline to 12 p-value 
Median Change (intar-quartile months 
range) Median Change 
( inter-quartile range) 
HWK (meters) 61.5 < 0.001 42.8 <0.001 
(15.6,107.7) (-15.1,115.6) 
QOL score - 22.5 < 0.001 -18 < 0.001 
(-42, -5.7) (-43.5, -7) 
NHYA class - 1.0 < 0.001 -1.0 < 0.001 
(-1.0, 0) (-2.0, -1.0) 
EXT (seconds) 120.5 < 0.001 106 0.007 
(40, 195) (14, 216) 
In addition, 57 pts originally randomized to the no-CRT group for the first 6 months of the 
study subsequently received 6 months of CRT. HWK, QOL, NYHA and EXT were all 
improved at 12 months as compared to Baseline (p<O.05) 
Conclusions: In pts with symptomatic CHF, systolic dysfunction and a prolonged QRS, 
CRT offers a sustained, long term improvement in patient well-being and exercise capac- 
ity. 
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1111-140 Lower Sinus Rate Af ter  In i t iat ion of  Left  Ventricular 
Pacing in Patients With Left  Bundle Branch Block and 
Advanced Heart Failure 
Andreas Schuchert. Muhammet All Aydin, Thomas Meinertz, University-Hospital 
Hamburg-Eppendorf, Hamburg, Germany. 
The hypothesis was that the improvement of left ventricular pacing in patients with 
advanced heart failure and left bundle branch block is associated with changes of sinus 
rate. The distribution of the sinus rate at month 1 stored in the rate histogram of the pace- 
maker was compared to the findings at month 12. The study included 31 patients with 
advanced heart failure and left bundle branch block. All patients received a specially 
designed pacing lead, which was placed in a side branch of the coronary sinus for left 
ventricular pacing. The lead was connected to a DDD pacemaker (Affinity DR, St. Jude 
Medical) in 8 and to a biventricular three-chamber pacemaker (Frontier 3x2, St. Jude 
Medical) in 23 patients. The pacemaker stored in the diagnostic counters the atdal rate 
histogram, which summadzes the heart rates from 55 to 70 bpm (H1), from 71 to 90 bpm 
(H 2), from 91 to 110 bpm (H 3), and from 110 to 131 bpm (H 4). 
RESULTS: The patients had at implantation NYHA class III (n= 9) or class IV (n = 22). 
Follow-up at month 12 is completed in 19 patients who had NYHA class I in 15 and class 
II in 4 patients. At hospital discharge, 25 patients were programmed to the DDD and 6 
patients to the DDDR mode. Lower pacing rate was programmed to 62 ± 8 ppm and 
upper pacing rate to 113 ± 4 ppm. Besides the reduction of diuretics there was no rele- 
vant modification of the prescribed medication. The percentage of atrial pacing was 26 ± 
41% of the time at month 1 and 35 ± 45 % of the time at month 12. The distribution of the 
atrial rate was at month 1 55 ± 20 % (H1), 39 ± 18 % (H 2), 5 ± 2 % (H 3), 2 ± 1% (H 4), 
and at month 12 78 ± 21% (H 1; p<0.05 vs month 1), 17 ± 15 % (H 2; p<0.05 vs month 
1), 4 ± 3 % (H 3), and 1 ± 1% (H 4). The DDDR mode was programmed in additional 4 
patients because of chronotropic incompetence during follow-up. There were no signifi- 
cent differences between patients with left and biventdcular pacing. 
CONCLUSIONS: There was a significant 45% decrease in the frequency from 71 to 90 
bpm and a significant increase in the frequency from 55 to 70 bpm dudng the first year 
follow-up. The findings indicate that the symptomatic improvement after left ventricular 
pacing is associated with lower sinus rate. 
1111-159 Detectable T ropon in  T Level  Predicts  High Mortality in 
Patients With Heart Failure Undergoing Internal 
Defibrillator Implantation 
Ali F. Sonel. Alaa Shalaby, Joseph P. McConnell, Scott Hogen, Arthur M. Feldman, 
University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, 
Mayo Clinic, Rochester, Minnesota. 
Background: Tropenin levels have been demonstrated to predict cardiac events in 
patients with ischemic as well as non-ischemic cardiomyopathy (CM). Arrhythmic death 
remains a leading cause of mortality in patients with CM. While implantable cardiac 
defibrillator (ICD) devices have been demonstrated to favorably impact mortality in cer- 
tain subsets of patients with CM, their mortality remains high. 
Methods: In an effort to study the predictive value of baseline troponin levels in patients 
who are candidates for ICD devices we collected baseline blood samples for tropenin T 
(TnT) and CK-MB in 52 consecutive patients immediately before successful pectoral 
transvenous ICD implant. Patients with any clinical evidence of an acute coronary syn- 
drome during the preceding 2 weeks were excluded from the study. All patients received 
ICDs for standard clinical indications. They subsequently received routine clinical follow 
up care, Patients were divided into two groups based on their TnT level prior to implanta- 
tion. Patients with non-detectable TnT <0.01 ng/ml) were classified as Group A, Patients 
with detectable TnT (_>0.01 ng/ml) were classified as study Group B. Patients were then 
followed for total mortality 
Results: All patients were males with mean age 68+/- 10 years. Mean ejection fraction 
was 29 +1- 12% and 65% had ischemic cardiomyopathy. Mean follow up duration was 17 
+/- 8 months. None of the patients had abnormal CK-MB mass (Mean 1.7 +/- 1.1 ng/ml). 
There were 37 patients in Group A and 15 patients in Group B (TnT 0.013-0.146 ng/ml). 
There was no difference between the groups A and B in terms of age (68 vs. 69, p=NS), 
ejection fraction (30 vs. 29%, p=NS) or proportion of patients with ischemic cerdiomyope- 
thy (68 vs. 60%, p=NS). There were no early post-operative deaths (within 30 days). Dur- 
ing follow up 16 (31%) patients died. Group A patients had 16% mortality(6/37) 
compared to 67% mortality (10/15) in Group B (p<0.001). 
Concluelone: In a cohort of male patients with CM undergoing ICD implantation for stan- 
dard clinical indications, presence of detectable TnT is associated with high mortality 
despite ICD implantation. TnT may be a useful marker for risk stratification of patients 
with CM prior to ICD implantation. 
1111-160 Acute  Ef fects  of Biventrlculer Pacing on Noninvasive 
Parameters of Left Ventricular Systolic Function 
Zoran B. PoDoyj~, Richard A. Grimm, George Perlic, Edward Chinchoy, Jing Ping Sun, 
Erwan Donal, Nell L. Greenberg, Bruce Wilkoff, James D, Thomas, The Cleveland Clinic 
Foundation, Cleveland, Ohio, Cleveland, Ohio. 
While invasive studies have shown that biventricular (BiV) pacing improves left ventricu- 
lar (LV) function in selected heart failure patients, such techniques cannot be applied rou- 
tinely. We sought to assess acute effects of BiV pacing by noninvasive techniques. 
Methods: Sixteen patients enrolled in InSync trial (age 64 ± 9 years, 3 females, EF <35% 
and QRS >130 ms) were studied one to 6 months after pacemaker implantation during 
BiV pacing, and while ventricular pacing was inhibited. Regional strains and displace- 
ments of the interventdcular septum (IVS), LV free wall, and right ventricular (RV) free 
wall were obtained from Color Doppler tissue imaging in a four-chamber view (System 
Five, GE). Peak power index was calculated as a product of simultaneously acquired 
noninvasive blood pressure (Finapres, Ohmeda) and PW Doppler of the LV outflow tract. 
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The z ratio was calculated as a sum of LV ejection and filling times divided by RR inter- 
val. 
Results: During pacing, average regional strain improved from -6.6 ± 9.4 to -8.8 ± 8.2 % 
(p = 0.02) (Figure), with no change in average regional displacement (0.41 ± 0.09 vs. 
0.42 ± 0.29, p = NS). Peak power index improved from 82 ± 28 to 94 ± 28 mmHgx m/s (p 
= 0.04) while systolic blood pressure increased from 106 ± 36 to 111 ± 32 mmHg (p = 
0.05). Finally, the z ratio increased from 0.76 ± 0.09 to 0.85 ± 0.04 (p = 0.002). 
Conclusion: Using novel, but widely available, noninvasive indices we demonstrated 
improvement in regional and global LV systolic function during biventricular pacing. 
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1111-161 Effect  o f  Beta-Blockade Therapy in Symptomatic Heart 
Fai lure Pat ients  With and Wi thout  Left  Bundle Branch 
Block 
Andreas Schuchert. for the BISEX Investigators, University-Hospital Hamburg- 
Eppendoff, Hamburg, Germany. 
Patients with advanced heart failure and left bundle branch block benefit from the implan- 
tation of a coronary sinus lead for electrical resynchronization. Most previous studies, 
however, included patients who had not yet received beta-blocker treatment. The aim of 
the present investigation was to compare the effect of beta-blocker treatment in patients 
with and without left bundle branch block on NYHA-class. The study included 382 out- 
clinic patients with advanced heart failure who already received an ACE inhibitor and 
diuretics. The patients received in 2-weeks interval increasing doses of bisoproIoI from 
1.25 mg to 10 mg daily, Mean follow-up was 27 weeks after initiation of beta-blocker 
treatment. 
Results: There were 107 (64 ± 9 years, male n = 70) patients with (LBBB) and 275 (62 ± 
10 years, male n = 201) patients without left bundle branch block (CON). The study was 
prematurely terminated in 18 (17%, LBBB) and 48 (17%, CON) patients, respectively. 
The reasons were adverse events (n--46), lost-to-follow-up (n=8), withdrawn consent 
(n=5) and various others (n=7). The mean follow-up time was 28 ± 10 weeks in the LBBB 
and 26 ± 11 weeks in the CON group. The maximal beta-blocker dose was 7.2 ± 3.2 mg 
(LBBB) and 7.1 ± 3.1 mg (CON) daily, respectively. Heart rate decreased from 81 ± 15 
(LBBS) and 80 ± 13 bpm (CON) by 14 bpm in each group. NYHA class I had 4 (4%) with 
and 16 (6%) without LBBB, NYHA class II 55 (51%) with and 158 (58%) without LBBB, 
NYHA class III 47 (44%) with and 101 (37%) without LBBB, and NYHA class IV 1 (1%) 
with and 0 without LBBB. At the final evaluation, NYHA class I had 31 (29%) with and 91 
(33%) without LBBB, NYHA class II 63 (59%) with and 167 (61%) without LBBB, NYHA 
class III 10 (9%) with and 16 (6%) without LBBB, and NYHA class IV 3 (3%) with and 1 
(0.4%) without LBBB. There were no significant differences in the improvement of the 
two groups. 
Conclusions: Patients with advanced heart failure and left bundle branch block had the 
same benefits from beta-blocker treatment compared to patients without left bundle 
branch block. Beta-blocker treatment should be initiated in these patients before an inva- 
sive resynchronization therapy is considered. 
1111-162 The Prevalence of Heart Fai lure in the Permanently 
Paced Population and the Uti l i ty of  BNP as a Screening 
Tool  
Simon D. Thackrav. Klaus K. Witte, Nikolay P. Nikitin, John G. Cleland, Academic 
Department of Cardiology, University of Hull, Kingston-upon-Ruff, United Kingdom. 
Background: We undertook a detailed clinical and echocardiographic screening study of 
patients with permanent ventricular pacemakers (PPM) to describe the prevalence of 
heart failure and the use of BNP as a screening tool. 
Method: 300 consecutive patients attending for routine follow up at a regional cardio-tho- 
racic centre were enrolled. Mode and duration of pacing were recorded along with symp- 
toms, medical history, 6-minute walk, n-terminal BNP, and a detailed echocardiogram. 
Results: 150 patients had a DDD device (mean age 69.3 SD 11.3 years) and 133 a VVI 
device (mean age 75,4 SD 12.2 years P=0.0015 for age). 69 patients (23%) had heart 
failure (HF), as defined by symptoms of breathlessness (NYHA class II, IIJ or IV) and a 
Simpson's hi-plane ejection fraction (LVEF) of 40% or less. Patients with HF had had a 
PPM for significantly longer (8.4 SD 6.8 vs, 3.9 SD 3.4 years P=0,0046), were more likely 
to have a VVI than a DDD PPM (26 of 150 DDD vs. 43 of 133 VVI chi squared=6.3, 
P=0.01) and a significantly reduced 6 minute walk distance 107 (66) m vs. 249 (146) m, 
P=O.0001. 
BNP data were analysed on 250 patients (125 DDD, 115 VVl and 10 others). Mean BNP 
values were higher in the VVl group (406 fmol/ml SD 504) vs. DDD (274 fmol/ml SD 233) 
P=0.001. BNP level was inversely correlated with LVEF in all patients (r = -0,409, 
p=0.001). This relationship was stronger in the DDD group (r = -0.62, P<0.001) than the 
VVI group(r = -0.24, P=0.06). Overall sensitivity (sn) and specificity (sp) of plasma SNP 
level for detecting HF was moderate in the paced population. Sub-group analysis by 
pacemaker type showed much-improved sp/sn in the DDD group. Values above 350 
fmol/ml (upper limit of normal) offered 69.2% Sn and 89.1% Sp (+ve predictive value 
0.64, -ve predictive value 0.91) in the DDD group, this increased to 72.7% / 92.8% (+ve 
PV 0.8, -ve PV 0.89) if as,symptomatic patients were excluded. 
Conclusion: Heart failure is present in neady a quarter of the paced population. Echocar- 
diographic screening of this 'at-dsk' population is justified to improve rates of diagnosis 
and treatment. N-terminal BNP may be a valuable adjunct in screening patients with a 
DDD pacemaker, offering good exclusion value for heart failure. 
POSTER SESSION 
1112 Cardiomyopathy and Myocardial Injury 
Monday, March 18, 2002, Noon-2:00 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: Noon-l:00 p.m. 
1112-151 The Sever i ty  of  Bra in  In jury  and Female Gender Predict 
Myocardial Necrosis After Subarachnoid Hemorrhage 
Povee P. Tuna, Alexander Kopelnik, Nader M. Banki, Kenneth C. Ong, Nerissa U. Ko, 
Michael T, Lawton, Daryl R. Gress, Barbara Drew, Elyse Foster, William W. Parmley, 
Jonathan G. Zaroff, UCSF Medical Center, San Francisco, Ca/ifomia. 
Background:. Cardiac injury is common after subarachnoid hemorrhage (SAH) and 17% 
of patients have elevated levels of cardiac troponin I (cTi). However, the clinical predic- 
tors of myocardial necrosis are unknown. The objective of this study was to determine 
the demographic, hemodynamic and neurologic factors that predict release of cTi. 
Methods:. We conducted a prospective cohort study of consecutive patients admitted to 
UCSF with SAH. Predictor variables reflecting demographic (age, gender), hemody- 
namic (phenylephdne dose, head rate, systolic blood pressure) and neurologic factors 
(Hunt-Hess clinical SAH severity score, 1-5) were acquired, The hemodynamic data was 
collected and cTi was measured on days 1, 3, and 6 after enrollment. Troponin I was 
treated as a dichotomous outcome variable (abnormal >0,3 ug/L). We performed bivad- 
ate and multivariate statistical analyses to determine the odds ratio (OR) for cTi release 
for each predictor variable. 
Results: The study subjects included 99 patients, 64 women and 35 men, with an aver- 
age age of 53. Elevated cTi levels occurred in 36.5% (range 0.4-50 ug/L), cTi was ele- 
vated in all four patients with Hunt-Hess grade 5 SAH (not modeled). The statistical 
results are shown below: 
Predictor Bivadate Analysis Multivariate Analysis 
OR 95% CI P OR 95% CI P 
Hunt-Hess 2 (vs.1) 0.64 0.11-3.49 0.604 0.44 0.07-2.78 0.389 
Hunt-Hess 3 (vs.1) 3.82 1.22-11.94 0.021 3.49 0.95-12.77 0.059 
Hunt-Hess 4 (vs.1) 9.11 2.38-34.85 0.001 10.29 2.14-49.53 0.004 
Female Gender 2.68 1.05-6.83 0,039 5.50 1.49-20.34 0.011 
Age (per 5/yr incr.) 1.01 0.86-1.19 0.878 0.84 0.64-1.09 0.183 
Peak Phenylephdne Dose 1.05 1.01-1.10 0.029 1.04 0.98-1.10 0.232 
(per 20mcg incr.) 
Peak Heart Rate 1.01 0.99-1.03 0.393 0.99 0.96-1.02 0.415 
Peak Systolic BP 1.01 0.99-1.02 0.396 1.01 0.99-1.04 0.334 
Conclusion: The severity of neurologic injury and female gender are strong independent 
predictors of myocardial necrosis in patients with SAH. Patients with these characteris- 
tics should be closely monitored for the development of cardiac dysfunction. 
1112-152 Card ioneuropathy  and Mi tochondr ia l  Phenotype 
Jose Marin-Gamia. Michael J. Goldenthal, The Molecular Cardiology and Neuromuscular 
Institute, Highland Park, New Jersey 
Cardiomyopathy and neuromuscular abnormalities (cardioneuropathy) may simulta- 
neously coexist and present with defects in mitochondrial DNA and bioenergetic function. 
Methods: A combined biochemical and molecular analysis of mitochondda was per- 
formed in 14 patients with both cardiomyopathy (8 with HCM, 6 with DCM) and neurolog- 
ical disorders including ataxia, seizures, dystonia, ophthalmoplegia, Kearns-Sayre 
syndrome (KSS) and Leigh disease. 
Results: All cardiac tissues analyzed (8 cases) showed defects in specific cardiac mito- 
chondrial respiratory complex activity (5 with multiple enzymes effected; 3 with a single 
enzyme effected). Both Leigh cases had defects in complex V associated with a mtDNA 
mutation at nt 8993; other pathogenic mtDNA mutations reported in mitochonddal dis- 
ease were not found. The most frequent cardiac enzyme effected was complex V (7 of 8 
cases). All skeletal muscle tissues analyzed (6 cases) had at least 2 respiratory enzymes 
effected with complex III most frequently effected (all 6). No pathogenic mtDNA point 
mutations were found in this group. However, two patients (with DCM and KSS) dis- 
played highly abundant, multiple large-scale skeletal muscle mtDNA deletions (including 
a novet 11 kb deletion) as well as reduced complex I,III and IV ectivities.Analysis of blood 
from one patient presenting with ataxia and DCM revealed multiple, abundant large-scale 
mtDNA deletions. 
Conclusion: Defects in mitochondrial DNA and bioenergetics are frequently present in 
cases of cardioneuropathy and may be causally related mainly in the presence of specific 
mtDNA point mutations (2) and deletions (4). Biochemical and molecular analysis of 
mitochondria is warranted in the evaluation of cardioneuropathy. 
